Pictet Asset Management Ltd. boosted its position in Acceleron Pharma Inc. (NASDAQ:XLRN) by 2.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 664,145 shares of the biopharmaceutical company’s stock after buying an additional 15,612 shares during the period. Pictet Asset Management Ltd.’s holdings in Acceleron Pharma were worth $16,942,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. TD Asset Management Inc. increased its stake in Acceleron Pharma by 0.8% in the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after buying an additional 600 shares during the last quarter. Tudor Investment Corp ET AL increased its stake in Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 716 shares during the last quarter. Teachers Advisors LLC increased its stake in Acceleron Pharma by 2.1% in the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after buying an additional 942 shares during the last quarter. American International Group Inc. increased its stake in Acceleron Pharma by 7.1% in the first quarter. American International Group Inc. now owns 16,878 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 1,119 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in Acceleron Pharma by 10.5% in the first quarter. Nationwide Fund Advisors now owns 22,737 shares of the biopharmaceutical company’s stock worth $602,000 after buying an additional 2,168 shares during the last quarter. 83.65% of the stock is currently owned by institutional investors and hedge funds.

Acceleron Pharma Inc. (XLRN) opened at 34.10 on Friday. The stock’s market cap is $1.32 billion. The company’s 50-day moving average price is $32.33 and its 200-day moving average price is $28.88. Acceleron Pharma Inc. has a 12-month low of $23.07 and a 12-month high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.12. Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. During the same period in the prior year, the business posted ($0.59) EPS. Acceleron Pharma’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, equities analysts expect that Acceleron Pharma Inc. will post ($2.73) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/13/pictet-asset-management-ltd-increases-stake-in-acceleron-pharma-inc-nasdaqxlrn.html.

A number of analysts have issued reports on the company. CIBC downgraded Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. Zacks Investment Research downgraded Acceleron Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday. Morgan Stanley cut their target price on Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Acceleron Pharma in a research report on Tuesday, June 13th. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $41.53.

In other Acceleron Pharma news, EVP Matthew L. Sherman sold 16,000 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total transaction of $512,000.00. Following the completion of the sale, the executive vice president now owns 112,400 shares of the company’s stock, valued at $3,596,800. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Ravindra Kumar sold 937 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $29,984.00. Following the sale, the senior vice president now directly owns 96,264 shares of the company’s stock, valued at approximately $3,080,448. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,402 shares of company stock valued at $2,105,416. Insiders own 3.90% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.